Literature DB >> 1103622

Hepatic disease in asymptomatic parenteral narcotic drug abusers: a Veterans Administration collaborative study.

L B Seeff, H J Zimmerman, E C Wright, E R Schiff, T Kiernan, C M Leevy, C H Tamburro, K G Ishak.   

Abstract

The Veterans Administration is currently conducting a collaborative study in three hospital-based drug treatment clinics to evaluate asymptomatic parenteral drug addicts for evidence of hepatic disease. Preliminary data are presented on 347 patients who have completed at least three months of follow-up evaluation. On admission, abnormal serum transaminase values were demonstrated in one half, HBs Ag in 7 per cent, and anti-HBs in 59 per cent. The frequency of these findings increased during the follow-up evaluation, only 19 (5.5 per cent) remaining entirely free of one or more of these abnormalities. Definable hepatologic disease (acute or chronic hepatitis, alcoholic hepatitis) developed in 46 per cent of the patients. However, among 60 of them subjected to liver biopsy, a poor correlation was noted between the clinical and histologic diagnoses. In particular, routine liver function and immunologic tests did not discriminate between histologically detected chronic active and chronic persistent hepatitis. However, HBs Ag was present significantly more frequently in those with chronic active hepatitis. Wide variability of histologic diagnoses was seen among patients subjected to more than one biopsy, apparent progression and regression of the lesion being noted. This demonstrates the hazard of attempting to assign a prognosis to the disease on the basis of a single liver biopsy specimen, and suggests that repeated biopsies should be mandatory for the evaluation of chronic liver disease in drug addicts.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1103622     DOI: 10.1097/00000441-197507000-00006

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  9 in total

1.  Hepatitis B virus immunization among young injection drug users in San Francisco, Calif: the UFO Study.

Authors:  Paula J Lum; Kristen C Ochoa; Judith A Hahn; Kimberly Page Shafer; Jennifer L Evans; Andrew R Moss
Journal:  Am J Public Health       Date:  2003-06       Impact factor: 9.308

2.  Hepatitis B as a hazard to laboratory staff: a re-appraisal.

Authors:  E A Follett; J D Sleigh
Journal:  J Clin Pathol       Date:  1980-11       Impact factor: 3.411

3.  Clinical, biochemical, serological, histological and ultrastructural features of liver disease in drug abusers.

Authors:  I V Weller; D Cohn; A Sierralta; M Mitcheson; M G Ross; L Montano; P Scheuer; H C Thomas
Journal:  Gut       Date:  1984-04       Impact factor: 23.059

4.  Trends in intravenous drug abuse as reflected in national hepatitis reporting.

Authors:  L Minichiello; R Retka
Journal:  Am J Public Health       Date:  1976-09       Impact factor: 9.308

5.  Epidemiological aspects of acute viral hepatitis in drug abusers.

Authors:  F Bortolotti; A Bertaggia; P Cadrobbi; C Crivellaro; E Pornaro; G Realdi
Journal:  Infection       Date:  1982 Sep-Oct       Impact factor: 3.553

6.  Chronic non-A, non-B hepatitis in drug addicts--a follow-up study.

Authors:  R Wejstål; J Lindberg; P Lundin; B G Hansson; G Norkrans
Journal:  Infection       Date:  1988 May-Jun       Impact factor: 3.553

7.  Hepatic cirrhosis in young adults: association with adolescent onset of alcohol and parenteral heroin abuse.

Authors:  D M Novick; R W Enlow; A M Gelb; R J Stenger; M Fotino; J W Winter; S R Yancovitz; M D Schoenberg; M J Kreek
Journal:  Gut       Date:  1985-01       Impact factor: 23.059

8.  Chronic hepatitis associated with drug abuse: significance of hepatitis B virus.

Authors:  D J Miller; H Kleber; J R Bloomer
Journal:  Yale J Biol Med       Date:  1979 Jan-Feb

9.  Epidemiologic study of hepatitis B in pregnant Korean women.

Authors:  Y H Chang; G S Choi; W J Jeong; K S Park; J W Kim; N K Joung; S Y Lee; H J Choi; D Y Choi; C Y Lim
Journal:  Korean J Intern Med       Date:  1986-07       Impact factor: 2.884

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.